Kevin Kirby has more than 25 years of experience in Medicare reimbursement, with a focus on Medicare Part B, particularly as it relates to pharmaceuticals and biotechnology. Kevin joined The Moran Company in late 1999 from Pharmacia & Upjohn, where he was Legislative Counsel. Kevin is the Managing Director of the firm.

Kevin’s work focuses on pharmaceutical, pharmacy and biotechnology policies, including Medicare reimbursement issues and policy and strategy development on various pieces of Medicare reform legislation. He was active in policy development for clients interested in issues that were affected by the Affordable Care Act and is in expert in a variety of drug reimbursement issues governed by the Medicare Modernization Act (MMA). He has provided quick turnaround analyses of various Medicare rule-making documents across a number of payment systems as well as expert advice targeted to particular companies and products, including assistance with Average Sales Price (ASP) reporting, 340B pricing, and the intersection of Medicare Part B with the Part D drug benefit.

Kevin provides legislative and regulatory analytical support on a variety of Medicare payment systems, including the Hospital Outpatient and Inpatient Prospective Payment Systems, the Medicare Physician Fee Schedule and a variety of related issue areas. Kevin has also assisted clients with Medicaid issues, focusing particularly on Average Manufacturer Price (AMP) and other issues related to pharmacy reimbursement.

Among a variety of other health policy issues, Kevin has also assisted clients with state prescription drug coverage and pricing concerns and helped to design government agency performance measurements. Kevin has also assisted in the drafting and editing of numerous white papers—including work on various matters related to the Health Insurance Portability and Accountability Act (HIPAA).
While with Pharmacia & Upjohn, Kevin had an opportunity to work on various health policy issues, including the Food and Drug Modernization Act, antibiotic resistance, and development of potential interim Medicare drug coverage options.

Kevin graduated magna cum laude from the Georgetown University Law Center in 1997. He received his bachelor’s degree cum laude from Loyola University Maryland. He is a member of the District of Columbia Bar.